Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.53 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29625934 | 1.00 | KMT2A (0.55) | KMT2AMEN1MAPTLMNASAE1 | |
| SCHEMBL29625919 | 0.92 | KMT2A (0.54) | KMT2AMEN1MAPTLMNASAE1 | |
| SCHEMBL23041013 | 0.92 | KMT2A (0.54) | KMT2AMEN1MAPTLMNASAE1 | |
| SCHEMBL21305508 | 0.91 | NPC1 (0.54) | KMT2AMEN1MAPTSMN1; SMN2KDR | |
| SCHEMBL29625930 | 0.91 | KMT2A (0.53) | KMT2AMEN1MAPTLMNASAE1 | |
| SCHEMBL23051405 | 0.91 | KMT2A (0.53) | KMT2AMEN1MAPTLMNASAE1 | |
| SCHEMBL23051397 | 0.90 | MEN1 (0.52) | KMT2AMEN1MAPTLMNASAE1 | |
| SCHEMBL23051396 | 0.86 | KMT2A (0.58) | KMT2AMEN1MAPTLMNASAE1 | |
| SCHEMBL23051408 | 0.85 | KMT2A (0.57) | KMT2AMEN1MAPTLMNASAE1 | |
| SCHEMBL10192075 | 0.83 | KMT2A (0.71) | KMT2AMEN1MAPTLMNASAE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324819-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2022-10-13 | — | — | US | disclosed |
| US-20220324819-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2022-10-13 | — | — | US | disclosed |
| EP-4021573-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | Alzecure Pharma AB (SE) | 2022-07-06 | — | — | EP | disclosed |
| CN-114423743-A | Triazine derivatives for the treatment of diseases associated with neurotrophic factors | 阿泽克制药公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2021038241-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021038241-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324819-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | KMT2A 3470/4885MEN1 2815/4885MAPT 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.